Healthcare provider profile · identity verified

Matthew D Schultz, MD

Family Practice · MORA, MN · NPI 1235129743

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	306	86
Lisinopril	Lisinopril	271	79
Omeprazole	Omeprazole	248	67
Amlodipine Besylate	Amlodipine Besylate	245	75
Losartan Potassium	Losartan Potassium	211	57
Levothyroxine Sodium	Levothyroxine Sodium	204	55
Rosuvastatin Calcium	Rosuvastatin Calcium	201	64
Hydrochlorothiazide	Hydrochlorothiazide	199	52
Metoprolol Succinate	Metoprolol Succinate	151	44
Albuterol Sulfate Hfa	Albuterol Sulfate	137	39
Metoprolol Tartrate	Metoprolol Tartrate	134	39
Tamsulosin Hcl	Tamsulosin Hcl	125	40
Gabapentin	Gabapentin	122	37
Furosemide	Furosemide	121	38
Eliquis	Apixaban	110	34
Potassium Chloride	Potassium Chloride	109	30
Metformin Hcl	Metformin Hcl	107	30
Simvastatin	Simvastatin	97	27
Warfarin Sodium	Warfarin Sodium	84	20
Carvedilol	Carvedilol	79	23
Fluticasone Propionate	Fluticasone Propionate	70	21
Sertraline Hcl	Sertraline Hcl	70	20
Allopurinol	Allopurinol	68	19
Spironolactone	Spironolactone	68	22
Montelukast Sodium	Montelukast Sodium	67	15
Atenolol	Atenolol	62	20
Metformin Hcl Er	Metformin Hcl	62	20
Pantoprazole Sodium	Pantoprazole Sodium	61	16
Pravastatin Sodium	Pravastatin Sodium	60	17
Famotidine	Famotidine	59	21
Ipratropium Bromide	Ipratropium Bromide	57	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	55	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	53	19
Trazodone Hcl	Trazodone Hcl	53	19
Duloxetine Hcl	Duloxetine Hcl	52	15
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	50	15
Ventolin Hfa	Albuterol Sulfate	50	18
Escitalopram Oxalate	Escitalopram Oxalate	47	14
Glipizide	Glipizide	44	suppressed
Jardiance	Empagliflozin	44	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	44	12
Oxycodone Hcl	Oxycodone Hcl	44	17
Hydralazine Hcl	Hydralazine Hcl	43	11
Clopidogrel	Clopidogrel Bisulfate	42	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	38	suppressed
Prednisone	Prednisone	35	20
Tramadol Hcl	Tramadol Hcl	35	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	33	suppressed
Nitroglycerin	Nitroglycerin	32	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	29	suppressed
Spiriva Handihaler	Tiotropium Bromide	29	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	29	suppressed
Finasteride	Finasteride	28	suppressed
Humalog Kwikpen U-100	Insulin Lispro	26	suppressed
Incruse Ellipta	Umeclidinium Bromide	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Mirtazapine	Mirtazapine	25	12
Propranolol Hcl Er	Propranolol Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	12
Lorazepam	Lorazepam	24	suppressed
Citalopram Hbr	Citalopram Hydrobromide	23	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	22	suppressed
Ozempic	Semaglutide	22	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	21	14
Alendronate Sodium	Alendronate Sodium	20	suppressed
Benazepril Hcl	Benazepril Hcl	20	suppressed
Digoxin	Digoxin	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Novolog Flexpen	Insulin Aspart	19	suppressed
Trulicity	Dulaglutide	19	suppressed
Bupropion Xl	Bupropion Hcl	18	suppressed
Diazepam	Diazepam	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	18	suppressed
Ibuprofen	Ibuprofen	18	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	18	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Symbicort	Budesonide/Formoterol Fumarate	17	suppressed
Torsemide	Torsemide	17	suppressed
Celecoxib	Celecoxib	16	suppressed
Divalproex Sodium Er	Divalproex Sodium	16	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Nystatin	Nystatin	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Naproxen	Naproxen	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	14	suppressed
Donepezil Hcl	Donepezil Hcl	14	suppressed
Mounjaro	Tirzepatide	14	suppressed
Pregabalin	Pregabalin	14	suppressed
Primidone	Primidone	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Darifenacin Er	Darifenacin Hydrobromide	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Dulera	Mometasone/Formoterol	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Norethindrone	Norethindrone	13	suppressed
Sotalol	Sotalol Hcl	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error